Traub Capital Management LLC Invests $278,000 in AstraZeneca PLC $AZN

Traub Capital Management LLC bought a new stake in AstraZeneca PLC (NASDAQ:AZN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,985 shares of the company’s stock, valued at approximately $278,000.

Other large investors have also added to or reduced their stakes in the company. Goldman Sachs Group Inc. raised its holdings in shares of AstraZeneca by 30.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock valued at $1,003,124,000 after buying an additional 3,224,251 shares in the last quarter. Valeo Financial Advisors LLC raised its stake in shares of AstraZeneca by 14,797.3% during the second quarter. Valeo Financial Advisors LLC now owns 2,322,638 shares of the company’s stock worth $162,306,000 after acquiring an additional 2,307,047 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of AstraZeneca by 2,389.9% in the 2nd quarter. Acadian Asset Management LLC now owns 2,043,850 shares of the company’s stock worth $142,798,000 after acquiring an additional 1,961,764 shares during the last quarter. American Century Companies Inc. boosted its stake in shares of AstraZeneca by 406.9% in the 1st quarter. American Century Companies Inc. now owns 2,020,629 shares of the company’s stock valued at $148,517,000 after purchasing an additional 1,621,974 shares in the last quarter. Finally, Jennison Associates LLC grew its holdings in shares of AstraZeneca by 15.2% during the 2nd quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock valued at $850,255,000 after purchasing an additional 1,605,133 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on AZN. Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday, October 16th. Finally, Jefferies Financial Group initiated coverage on AstraZeneca in a research note on Monday, October 27th. They set a “buy” rating for the company. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Trading Up 0.2%

NASDAQ AZN opened at $89.55 on Wednesday. The stock has a market cap of $277.73 billion, a P/E ratio of 33.67, a price-to-earnings-growth ratio of 1.52 and a beta of 0.34. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $90.27. The stock has a 50 day simple moving average of $82.45 and a two-hundred day simple moving average of $76.49. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Thursday, November 6th. The company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. The company had revenue of $15.19 billion during the quarter, compared to the consensus estimate of $14.75 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.08 earnings per share. On average, analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.